Document is current
Any future updates will be listed below
-
Authors
Wong, Bin Sheng https://orcid.org/0000-0003-4074-3223
Shah, Sagar R.
Yankaskas, Christopher L.
Bajpai, Vivek K. https://orcid.org/0000-0003-4659-3211
Wu, Pei-Hsun https://orcid.org/0000-0002-7371-2960
Chin, Deborah
Ifemembi, Brent
ReFaey, Karim https://orcid.org/0000-0001-7227-1529
Schiapparelli, Paula
Zheng, Xiaobin
Martin, Stuart S.
Fan, Chen-Ming https://orcid.org/0000-0003-3211-6617
Quiñones-Hinojosa, Alfredo https://orcid.org/0000-0003-4262-5968
Konstantopoulos, Konstantinos https://orcid.org/0000-0003-2623-1459
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (CA160997)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA124704, R01-CA216855, R01-CA216855, R01-CA183804)
A.Q.H. was also supported by the Mayo Clinic Clinician Investigator Award and the William J. and Charles H. Mayo Professorship
- License Information
-
More Information
Article History
Received: 25 February 2019
Accepted: 1 September 2020
First Online: 28 September 2020
Competing interests
: MAqCI is the subject of US utility patent applications 15/780,768 and 14/906,055. Intellectual property related to MAqCI is owned by the Johns Hopkins University and licenced to RecurX Bio, Inc., of which K.K. is a co-founder, consultant and board member. K.K. has a financial interest in RecurX Bio, Inc., which is subject to certain restrictions under university policy. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
